MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
3.270
+0.280
+9.36%
After Hours: 3.360 +0.09 +2.75% 19:48 06/26 EDT
OPEN
2.980
PREV CLOSE
2.990
HIGH
3.550
LOW
2.970
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
24.00
52 WEEK LOW
1.790
MARKET CAP
17.45M
P/E (TTM)
-0.1259
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at MBRX last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at MBRX last week (0608-0612)?
Weekly Report · 06/15 10:17
Weekly Report: what happened at MBRX last week (0601-0605)?
Weekly Report · 06/08 10:13
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
TipRanks · 06/05 13:01
Moleculin market research shows oncologists likely to prescribe Annamycin in relapsed/refractory AML
PUBT · 06/05 12:29
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Barchart · 06/05 07:29
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.